In EZH2-resistant cells, EZH2 inhibitors such as GSK126 and tazemetostat fail to inhibit the development of diffuse large B-cell lymphoma (DLBCL) cells, with a significant reduction of apoptosis (106). This evidence concerns the gene EZH2 and diffuse large B-cell lymphoma.